30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased
Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life.
Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health.
The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein.
This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily intake of spermidine. Spermidine is associated with benefits to longevity, cardiovascular health and brain health.
The paper states that “during (Almased’s) proteolytic enzyme procedure, bioactive and biogenic peptides, which were not detectable before in the raw materials, naturally occur. It can be assumed that the production process is significant in producing bioactive compounds responsible for unexpected positive effects on the metabolism, even in people who are not overweight”.
Other key findings in the 2022 review in Heliyon have shown:
- 167% increase in GLP-1 production and a 358% increase in PYY production (a satiety-induced hormone produced in the intestine) compared to consuming a standard American diet containing the same amount of calories by the same individuals (Oliveira et al. 2022)
- Almased group lost 145% more weight than the control group (-13lbs vs. -5.3lbs) in 12 weeks. Fat loss was 181% more in the Almased group (-9.9 lbs) than in the control group (-3.52 lbs) over the same period of time despite comparable weights before the study (Röhling et al. 2020)
- Almased plus resistance training increased muscle strength by 33% versus resistance training alone (Deibert et al 2010)
- Waist circumference reduction 239% greater in the Almased group compared to a fat-reduced diet (2.4in vs. 0.7in) after 6 weeks. Fat mass loss was 82% greater in the Almased group compared to a fat-reduced diet (11.2lbs vs. 6.1lbs) after 6 weeks (König et al 2008)
- A study on post-menopausal women saw a 62% reduction in the prevalence of metabolic syndrome and significant fat loss without losing lean mass (Deibert et al. 2007)
- Almased reduced liver fat content by an average of 56% and supports a healthy inflammatory response (Deibert et al 2019)
- Almased preserved 100% muscle mass while losing weight (Deibert et al 2004)
Researchers found that Almased improves the fat burning process so you burn fat and calories more effectively (Oliveira et al 2021). In overweight and obese individuals, Almased meal replacement regimens resulted in greater reductions in body weight, body mass index (BMI), and fat mass compared to traditional low-calorie diets, while also improving glycemic control and lipid profiles.
Beyond weight management, the review highlights Almased’s role in supporting healthy blood sugar levels in both prediabetic and type 2 diabetic individuals. This indicates Almased is safe for people with diabetes.
The review also notes Almased’s unique anti-aging and wellness benefits. Regular use has been linked to healthy cell function, reduced stress markers, and better overall energy and mood. Almased’s protein-rich formula, containing essential amino acids and bioactive peptides, supports muscle preservation, cellular health, and supports a healthy inflammatory response, contributing to improved quality of life and longevity.
“The results presented underscore the efficacy of the soy-yogurt-honey formula (Almased) in weight management and the improvement of obesity-associated cardiovascular disease and metabolic risk factors.” said the study’s authors.
About Almased
Founded over 30 years ago in Germany by holistic therapist Hubertus Trouillé, and his son Andre Trouillé, Almased is a family-owned and operated company dedicated to promoting health and wellness worldwide. Recognized as Europe’s #1 science backed weight-loss meal replacement shake brand, Almased combines natural ingredients with a patented fermentation process to deliver high-quality, effective nutrition. With over 30 peer reviewed studies across 3 decades, Almased is a global leader in metabolic health. With a commitment to sourcing the highest quality ingredients in the world, Almased continues its mission to help people achieve healthier, happier lives with clean, sustainable products.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250716374177/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global ETF Assets Tracking MSCI Equity Indexes Exceed $2 Trillion16.7.2025 14:19:00 CEST | Press release
The assets in indexed equity exchange-traded funds (ETFs) linked to MSCI’s global equity indexes surpassed $2 trillion, a growth rate of 17 percent since the start of 2025. This growth demonstrates that MSCI indexes are well positioned for investors seeking global opportunities. Asset growth has been driven by investor interest in products targeting developed markets equities outside the U.S., followed by emerging markets. More than $17 trillion of assets are benchmarked against MSCI indexes, including non-ETF products, other asset classes including fixed income and actively managed funds. “We are proud to be the index partner of choice for investors looking to stay ahead of global market transformations across regions, countries and sectors,” said Henry Fernandez, Chairman and Chief Executive Officer at MSCI. “Through a research-driven approach and active client engagement, we deliver and support the indexes our clients need to understand emerging and long-term opportunities across gl
ITRS Recognized in 2025 Gartner® Magic Quadrant™ for Observability Platforms for the First Time16.7.2025 14:00:00 CEST | Press release
ITRS, a pioneer in real-time monitoring and observability for mission-critical industries, today announced its inclusion in the 2025 Gartner® Magic Quadrant™ for Observability Platforms. ITRS’s transformation into a unified observability platform, purpose-built for demanding and regulated IT environments, is the outcome of sustained investment in product innovation. By consolidating Geneos (application performance), Opsview (infrastructure monitoring), and Uptrends (digital experience monitoring) into a single, powerful platform, ITRS Analytics, the company delivers observability at the speed of the markets. “Our ambition is to redefine observability for industries where downtime isn’t an option,” said Ryan Terpstra, CEO at ITRS. “ITRS Analytics empowers organizations to move beyond IT monitoring to holistic observability, ensuring the systems that power the modern digital economy are always on.” Built for Real-Time Resilience ITRS Analytics offers the ability to ingest and enrich tele
Venture Global and Eni Announce 20-Year LNG Sales and Purchase Agreement16.7.2025 13:00:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) and Eni S.P.A. of Italy announced the execution of a new Sales and Purchase Agreement (SPA) for the purchase of 2 million tonnes per annum (MTPA) of liquefied natural gas (LNG) from CP2 LNG, Venture Global’s third project, for 20 years. This deal marks Eni’s first ever long-term agreement with a U.S. LNG producer. To date, approximately 13.5 MTPA of CP2 Phase One has been sold, raising the total contracted capacity for all of Venture Global’s projects to 43.5 MTPA. To date, Venture Global has supplied Italy with nearly 40 cargoes of U.S. LNG from its Calcasieu Pass and Plaquemines LNG facilities. “We are honored that Eni, a leading innovator and global gas player, has chosen Venture Global as their first American LNG supplier. Italy is an important ally and trading partner to the United States, and we are grateful for the trust of Eni as our newest customer. This deal marks a significant milestone for the company and is further recognition of our
Veranex Unveils MedTech’s First Innovation CRO (iCRO)—Redefining R&D in a Capital‑Tight Market16.7.2025 13:00:00 CEST | Press release
Veranex, a global provider of product development and contract research services, today introduced the industry’s first Innovation CRO (iCRO)—an integrated development and research platform engineered to move medical devices and in-vitro diagnostics (IVDs) from concept to commercial success faster, with tighter budget control and a built-in path to payer adoption. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716366338/en/ Veranex launches Innovation CRO for device and diagnostics. iCRO: Innovation Without Waste The Veranex iCRO model is built on four core pillars: Speed & Capital Efficiency – Integrated teams and workflows can cut 3–6 months per development phase and reduce budget variance 18 percent versus transactional (traditional) outsourcing. Flexible partnership tiers—Full Stack, Stage Select, and Strategic Augment—let sponsors deploy only the iCRO services they need while retaining velocity. Evidence Integration
Pluto Labs' 'Strategic Efficiency' AI Outperforms Google & Anthropic Models at a Fraction of the Cost16.7.2025 12:47:00 CEST | Press release
— Achieves decisive victory in key scientific benchmarks, delivering highly practical and experimentally testable ideas with unparalleled cost-efficiency. Global commercial launch slated for Q3 2025, leveraging an existing platform of 170,000 researchers. In the global race to create an 'AI Scientist' capable of independent scientific discovery, Korean startup Pluto Labs is making significant waves. While tech giants like Google and Anthropic define competitive strength by sheer computing power, Pluto Labs introduces 'Scinapse AI,' a groundbreaking model that develops a more effective AI Scientist at just one-tenth of the usual computational cost, achieving overwhelming performance against top models in blind evaluations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715211709/en/ GRAPH: Scientific Idea Generation Performance Comparison - Scinapse AI vs. Google Gemini 2.5 Pro vs. Claude Opus 4 (Evaluation conducted by Pl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom